ClinicalTrials.gg
CompletedNCT00047840Updated Aug 25, 2016

This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Non-small Cell Lung Cancer.

A Phase 2 interventional study of ZD6474 and Placebo in Non-Small Cell Lung Cancer (NSCLC, Locally Advanced or Metastatic, Second-line, sponsored by Genzyme, a Sanofi Company. Completed at 26 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-08-25.

Sponsored by Genzyme, a Sanofi Company (part of Sanofi) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
129
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 24 studies testing vandetanib in Carcinoma, Non-Small-Cell Lung — none open to participants now, none under way, none of them phase 3. vandetanib · Carcinoma, Non-Small-Cell Lung.

Enrollment
7th of 23
129 · median 53
Started
2002
the only one that year
Phase 2
12 of 24
none open now
Registered
1st of 24
by date
Lead sponsor
12 of 24
Genzyme, a Sanofi Company

Among the 24 studies testing vandetanib in Carcinoma, Non-Small-Cell Lung, this one is the 7th largest by enrollment of the 23 interventional ones that give a count, is the only one that started in 2002, is one of 12 in phase 2, and was the 1st registered.

Carcinoma, Non-Small-Cell Lung

7,635 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

None of the 24 studies testing vandetanib in Carcinoma, Non-Small-Cell Lung is open now. The open studies under Carcinoma, Non-Small-Cell Lung, anywhere →

About vandetanib

vandetanib: first FDA approval 2011 (CAPRELSA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 989 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 24 studies testing vandetanib in Carcinoma, Non-Small-Cell Lung as a file.
02

Study summary

The purpose of this study is to assess the efficacy and safety of ZD6474 in patients with NSCLC after Failure of Prior Platinum-based Chemotherapy.

03

Conditions studied

  • Non-Small Cell Lung Cancer (NSCLC, Locally Advanced or Metastatic, Second-line
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histologic or cytologic confirmation of NSCLC (locally advanced or , IB-IV)
  • Failure of platinum-based chemotherapy

Exclusion criteria

Exclusion Criteria:

  • Mixed small cell or non-small-cell histology
  • Bronchoalveolar carcinoma
  • Prior chemotherapy or herbal preparations must be discontinued more than 4 weeks before the start of study therapy (6 weeks for nitrosoureas, mitomycin and suramin)
  • Prior treatment with docetaxel
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
129 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Outcome Progression free survival

Secondary outcomes

  1. Incidence and type of adverse events (Aes), clinically significant laboratory abnormalities, and ECG changes;

  2. Objective response rate and duration of response

  3. QoL and lung cancer subscale (LCS) from the FACT-L questionnaire

  4. WHO performance status

  5. Time to death

07

Study locations

26 sites
  • Research Site
    Los Angeles, California, United States
  • Research Site
    Jacksonville, Florida, United States
  • Research Site
    Atlanta, Georgia, United States
  • Research Site
    New Orleans, Louisiana, United States
  • Research Site
    Boston, Massachusetts, United States
  • Research Site
    Pittsfield, Massachusetts, United States
  • Research Site
    Ann Arbor, Michigan, United States
  • Research Site
    Detroit, Michigan, United States
  • Research Site
    Billings, Montana, United States
  • Research Site
    Great Neck, New York, United States
  • Research Site
    New York, New York, United States
  • Research Site
    Durham, North Carolina, United States
  • Research Site
    Coos Bay, Oregon, United States
  • Research Site
    Philadelphia, Pennsylvania, United States
  • Research Site
    Pittsburgh, Pennsylvania, United States
  • Research Site
    Houston, Texas, United States
  • Research Site
    Brno, Czech Republic
  • Research Site
    Chomutov, Czech Republic
  • Research Site
    Hradec, Czech Republic
  • Research Site
    Ostrava, Czech Republic
  • Research Site
    Plzen, Czech Republic
  • Research Site
    Praha, Czech Republic
  • Research Site
    Budapest, Hungary
  • Research Site
    Debrecen, Hungary
  • Research Site
    Deszk, Hungary
  • Research Site
    Torokbalint, Hungary
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2002 and a completion of Sep 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2002
First posted
Oct 24, 2002
Start
Oct 2002
CompletionActual
Sep 2006
Last update
Aug 25, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 25, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00047840
Responsible party
Sponsor
First posted
Oct 24, 2002
Start date
Oct 2002
Completion
Sep 2006
Last update
Aug 25, 2016

Study contacts

Clinical Sciences & Operations
study director · Sanofi
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Vandetanib · Docetaxel

Start the discussion